V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Phase 3 Completed 1027 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupOpen-labelPrevention

Summary

The study is being conducted to demonstrate that V221 may be administered concomitantly with pneumococcal conjugate vaccine without impairing the safety or immunogenicity of measles, mumps, rubella, varicella, or the 7 serotypes of S. pneumoniae.

Timeline

Start: 2006-03
Primary completion: 2007-09
Completion: 2007-09

Publications

Results Leonardi M, Bromberg K, Baxter R, Gardner JL, Klopfer S, Nicholson O, Brockley M, Trammel J, Leamy V, Williams W, Kuter B, Schodel F. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics. 2011 Dec;128(6):e1387-94. doi: 10.1542/peds.2010-2132. Epub 2011 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prevnar 13	Vaccine	0.5 ml	Intramuscular
Subject	ProQuad	Vaccine	0.5 ml	Subcutaneous

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Summary

Timeline

Publications

Drugs

Indications